Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Natural history, survival, and mortality
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Natural history, survival, and mortality

2 evidence topics · 4 sources

Transplant access and unmet need: background studies

“we found 1597 additional sensitized (CPRA 50–<99.9%) candidates with meaningfully lower than average access to transplant” (opens the source at this quote in a new tab)

“Although the TR increased sharply for the CPRA 99.9%+ group with KAS, it remained markedly lower than the average despite national priority.” (opens the source at this quote in a new tab)

Waiting time and mortality risk

“longer time waiting for a suitable donor relates to an increased mortality risk.” (opens the source at this quote in a new tab)